Voices
Jianjiao Ni: Local Consolidative Therapy as a Precision Strategy in IV NSCLC, with Eric K. Singhi and Kyle G. Mitchell
Jianjiao Ni, Eric K. Singhi, Kyle G. Mitchell

Jianjiao Ni: Local Consolidative Therapy as a Precision Strategy in IV NSCLC, with Eric K. Singhi and Kyle G. Mitchell

Jianjiao Ni, Radiation oncologist, MD candidate at Peking Union Medical College shared a post by Eric K. Singhi, Assistant Professor at MD Anderson Cancer Center on X, adding:

“More RCTs are warranted to further test this hypothesis and we are currently designing such trials”

Quoting Eric K. Singhi‘s post:

“A deceptively simple question in thoracic oncology: “Should patients with stage IV NSCLC receive more than systemic therapy alone?”

Our ASCO editorial argues local consolidative therapy is a precision strategy, for the right patient at the right time.”

Jianjiao Ni: Local Consolidative Therapy as a Precision Strategy in IV NSCLC, with Eric K. Singhi and Kyle G. Mitchell

Title: Local Consolidative Therapy in EGFR-Mutant NSCLC: Selecting the Right Patient at the Right Time

Authors: Eric K. Singhi, Kyle G. Mitchell

Read The Full Article

Jianjiao Ni: Local Consolidative Therapy as a Precision Strategy in IV NSCLC, with Eric K. Singhi and Kyle G. Mitchell

More posts featuring Jianjiao Ni and Eric K. Singhi on OncoDaily.

cancer Eric K. Singhi IV NSCLC Jianjiao Ni Kyle G. Mitchell NSCLC OncoDaily Oncology RCT